Savara, Inc. (SVRA): Price and Financial Metrics


Savara, Inc. (SVRA)

Today's Latest Price: $1.38 USD

0.08 (6.15%)

Updated Nov 24 4:00pm

Add SVRA to Watchlist
Sign Up

Overall POWR Rating

Sign Up to See Ratings...FREE!

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

SVRA Stock Price Chart Interactive Chart >

Price chart for SVRA

SVRA Price/Volume Stats

Current price $1.38 52-week high $5.48
Prev. close $1.30 52-week low $0.92
Day low $1.32 Volume 690,000
Day high $1.50 Avg. volume 355,862
50-day MA $1.15 Dividend yield N/A
200-day MA $1.94 Market Cap 74.71M

Savara, Inc. (SVRA) Company Bio

Savara Inc., a clinical-stage specialty pharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The company is based in Austin, Texas.

Most Popular Stories View All

• The 3 Best Stocks to Buy for December

• 2 Reasons Investors DON’T Care About Covid-19 Anymore

• 4 "Buy Rated" Clean Energy Stocks to Invest in for 2021

• Are Shares of CVS Still a Buy After the Launch of Amazon Pharmacy?

• 3 Stocks that Will Benefit as Bitcoin Skyrockets

View All Top Stories

SVRA Latest News Stream

Event/Time News Detail
Loading, please wait...
View All SVRA News

SVRA Latest Social Stream

Loading social stream, please wait...

View Full SVRA Social Stream

Latest SVRA News From Around the Web

Below are the latest news stories about Savara Inc that investors may wish to consider to help them evaluate SVRA as an investment opportunity.

Savara Announces Senior Management Changes

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Rob Neville has resigned as the Company’s Chief Executive Officer (CEO) and from the Board of Directors, effective immediately, to pursue other opportunities. The Company’s Board of Directors has appointed Matthew Pauls as Chairman and Interim CEO. Mr. Pauls has served as a member of Savara’s Board of Directors since 2017 and is a seasoned biopharmaceutical leader with extensive expe

Business Wire | September 11, 2020

Savara to Present at the 22nd Annual H.C. Wainwright Annual Investment Conference Being Held Virtually

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Savara management will be presenting at the H.C. Wainwright Annual Investment Conference on Wednesday, September 16, 2020 at 3:00 PM EDT/12:00 PM PDT. Interested parties can access a live audio webcast on the Investors page of the Savara website at www.savarapharma.com/investors/events-presentations/. Please connect to the Company's website at least 15 minutes prior to the start of t

Business Wire | September 9, 2020

Savara Announces New England Journal of Medicine (NEJM) Publication of IMPALA Study Results

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that results from the Phase 3 IMPALA study were published online in NEJM. The manuscript, titled “Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis,” appears in the September 7, 2020 online version of the publication and can be found at www.nejm.org. The IMPALA study evaluated molgramostim nebulizer solution (an inhaled granulocyte-macrophage colony-stimulating fac

Business Wire | September 8, 2020

The Daily Biotech Pulse: AbbVie In-licenses I-Mab's Cancer Drug, Savara Pulls The Plug On Cystic Fibrosis Study

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 3) Akouos Inc (NASDAQ: AKUS ) FibroGen Inc (NASDAQ: FGEN )(reacted to an adverse clinical readout for a rival drug to treat chronic kidney disease related anemia) Generation Bio Co (NASDAQ: GBIO ) Immunovant Inc (NASDAQ: IMVT ) Sutro Biopharma Inc (NASDAQ: STRO ) ( reacted to announcement concerning presentation of positive data for ovarian cancer drug) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 3) Akebia Therapeutics Inc (NASDAQ: AKBA ) (announced negative safety results for a late-stage study of drug to treat chronic kidney disease-induced anemia) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC ) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT ) Genfit SA (NASDA...

Benzinga | September 4, 2020

Savara Inc (SVRA) CEO Robert Neville on Q2 2020 Results - Earnings Call Transcript

Savara Inc (SVRA) Q2 2020 Results Conference Call August 06, 2020 04:30 PM ET Company Participants Anne Erickson - Head Investor Relations Robert Neville - Chief Executive Officer Badrul Chowdhury - Chief Medical Officer Taneli Jouhikainen - President and Chief Business Officer David Lowrance - Chief Financial Officer Presentation Operator...

SA Transcripts on Seeking Alpha | August 7, 2020

Read More 'SVRA' Stories Here

SVRA Price Returns

1-mo 18.97%
3-mo -1.43%
6-mo -43.44%
1-year 36.63%
3-year -88.41%
5-year -95.42%
YTD -69.20%
2019 -40.82%
2018 -48.99%
2017 135.56%
2016 -78.57%
2015 -25.00%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9199 seconds.